TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2010 - 2026)

TherapeuticsMD (TXMD) has reported Liabilities from Discontinued Operations for 7 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities from Discontinued Operations fell 2.02% year-over-year to $2.7 million; the trailing twelve-month figure through Jun 2026 stood at $2.7 million (down 2.02% YoY), and the FY2025 full-year result was $2.7 million, down 4.1% from the prior year.
• Liabilities from Discontinued Operations steadied at $2.7 million in Q2 2026 per TXMD's latest filing, from $2.7 million in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at $25.8 million in Q4 2022 and bottomed at $1.4 million in Q2 2023.
• Historically, Liabilities from Discontinued Operations has averaged $5.0 million across 5 years, with a median of $2.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities from Discontinued Operations tumbled 85.7% in 2023, then jumped 337.61% in 2024.
• Over 5 years, Liabilities from Discontinued Operations stood at $25.8 million in 2022, then sank by 85.7% to $3.7 million in 2023, then retreated by 24.72% to $2.8 million in 2024, then dropped by 4.1% to $2.7 million in 2025, then changed by 0.0% to $2.7 million in 2026.
• According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered $2.7 million, $2.7 million, and $2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.